Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 7, 2020 - The FDA announced the approval of Genentech’s Evrysdi (risdiplam), for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.
Return to publications